Inavolisib for previously treated pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new pill called inavolisib for people with pancreatic cancer that has grown after chemotherapy. The goal is to see if it can help shrink or control the cancer, and to check for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of pancreatic cancer called pancreatic ductal adenocarcinoma.
- Your cancer has grown or spread after at least one round of chemotherapy.
- You are 18 years or older and able to provide a sample of your tumor for testing.
- You are physically active and able to take care of yourself (performance status 0 or 1).
- You have not taken certain other targeted cancer drugs (PI3K, AKT, mTOR, RAS, or BRCA inhibitors) before.
- You do not have diabetes requiring medication, or a history of type 1 diabetes or pre-diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a combination of three drugs (serplulimab, bevacizumab, and a chemotherapy regimen) for people with pancreatic cancer that has spread or cannot be removed. It is for those who have already had one prior treatment and aims to see if this new combination can help control the cancer.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This study tests a new drug called IBI343 compared to a placebo (inactive substance) for people with advanced pancreatic cancer that has a specific protein (CLDN18.2) and has not responded to earlier treatments. The goal is to see if IBI343 can help slow the cancer's growth.
This trial tests a new drug, IBI343, combined with chemotherapy for people with advanced pancreatic cancer that has gotten worse after first-line treatment. It looks at whether this combination can help shrink tumors or slow cancer growth.
This trial tests a targeted pill called inavolisib for advanced or recurrent endometrial cancer that has a specific genetic change (PIK3CA mutation). The drug may block cancer growth by targeting this change, and the study aims to see if it helps people who have already tried platinum chemotherapy.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.